Cardio Diagnostics Holdings stock analysis
Cardio Diagnostics Holdings (CDIO) Stock Price & Analysis
CDIO Stock Chart & Stats
- Day’s Range
- $1.53 - $1.68
- 52-Week Range
- $0.97 - $7.91
- Previous Close
- $1.65
- Volume
- N/A
- Average Volume (3M)
- 21.32K
- Market Cap
- $4.88M
- Enterprise Value
- -$2.44T
- Total Cash (Recent Filing)
- $3.94M
- Total Debt (Recent Filing)
- $238.88K
- Price to Earnings (P/E)
- ―
- Beta
- 2.17
- Next Earnings
- N/A
- EPS Estimate
- N/A
- Next Dividend Ex-Date
- N/A
- Dividend Yield
- N/A
Cardio Diagnostics Holdings News
Cardio Diagnostics releases whitepaper on coronary heart disease detection
Cardio Diagnostics (CDIO) Holdings released a new whitepaper, The Invisible Burden of Non-Obstructive Coronary Artery Disease: Addressing Clinical Gaps in Coronary Angiography to Improve Patient Outcomes. The whitepaper is a
Cardio Diagnostics announces official launch of in-house laboratory in Iowa
Cardio Diagnostics (CDIO) announced the official launch of its in-house, high complexity CLIA-certified laboratory in Iowa City, Iowa. The new facility gives Cardio Diagnostics end-to-end control over the processing of
Cardio Diagnostics Holdings (NASDAQ: CDIO) Showcases Precision Cardiovascular Solutions for Employers, Health Plans
Austin, Texas, United States, July 1st, 2026, FinanceWire Cardio Diagnostics Holdings (NASDAQ: CDIO) is a precision cardiovascular medicine company leveraging epigenetics, genetics and artificial intelligence. The company discussed innovative approaches to cardiovascular
Cardio Diagnostics Holdings (NASDAQ: CDIO) Leverages Epigenetics to Reveal Hidden Heart Disease Risks
Austin, Texas, United States, June 30th, 2026, FinanceWire Cardio Diagnostics has positioned the science of epigenetics at the center of its diagnostic platform. Looking at an individual person’s epigenetics can
Cardio Diagnostics Holdings (NASDAQ: CDIO) Brings Molecular Precision to a Blind Spot in Coronary Heart Disease Detection
Austin, Texas, United States, June 29th, 2026, FinanceWire For decades, cardiovascular risk assessment has centered on a checklist of factors never designed to capture the full biological picture of how
Cardio Diagnostics Holdings (NASDAQ: CDIO) Expands Coverage of Precision Cardiovascular Tests Through Atlas Healthcare Physicians
Austin, Texas, United States, June 24th, 2026, FinanceWire Cardio Diagnostics Holdings (NASDAQ:CDIO), an AI-powered precision cardiovascular medicine company, announced that Atlas Healthcare Physicians, an independent physician association serving managed care
Cardio Diagnostics announces AHP to cover Epi+Gen CHD, PrecisionCHD
Cardio Diagnostics (CDIO) Holdings announces that Atlas Healthcare Physicians, AHP, will cover Cardio Diagnostics’ tests, Epi+Gen CHD and PrecisionCHD, for their members with prior authorization beginning May 2026. Published first
Cardio Diagnostics Holdings (NASDAQ: CDIO) Targets a $393B Heart Disease Problem with Epigenetics and AI
Austin, Texas, United States, June 23rd, 2026, FinanceWire For cardiovascular conditions, annual health care costs are forecasted to increase from $393 billion in 2020 to $1.4 trillion by 2050, almost
Cardio Diagnostics Holdings (NASDAQ: CDIO) Aligns with Growing Shift Toward Predictive, Precision Medicine
Austin, Texas, United States, June 18th, 2026, FinanceWire Cardio Diagnostics Holdings (NASDAQ: CDIO) is focused on personalized, data-driven cardiovascular care powered by artificial intelligence, epigenetics and genetic insights. “Through its proprietary platform
Cardio Diagnostics Holdings (NASDAQ: CDIO) Working to Help Employers Tackle Cardiovascular Risk, Healthcare Costs
Austin, Texas, United States, June 16th, 2026, FinanceWire Cardiovascular disease remains one of the most expensive health conditions in the United States. Cardio Diagnostics announced plans to participate in four
CDIO FAQ
What was Cardio Diagnostics Holdings’s price range in the past 12 months?
What is Cardio Diagnostics Holdings’s market cap?
When is Cardio Diagnostics Holdings’s upcoming earnings report date?
Is Cardio Diagnostics Holdings overvalued?
Does Cardio Diagnostics Holdings pay dividends?
What is Cardio Diagnostics Holdings’s EPS estimate?
How many shares outstanding does Cardio Diagnostics Holdings have?
Which hedge fund is a major shareholder of Cardio Diagnostics Holdings?
What is the TipRanks Smart Score and how is it calculated?
Company Description
Cardio Diagnostics Holdings
Cardio Diagnostics Holdings, Inc. specializes in creating and bringing to market advanced clinical diagnostic tools that leverage epigenetic insights to address cardiovascular disease. Among their key offerings is Epi+Gen CHD, a test designed to assess an individual's three-year risk for developing symptomatic coronary heart disease. This company, headquartered in Chicago, Illinois, was established in 2017.
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Meeshanthini V. Dogan
- Employees
- 15
- Website
- www.cdio.ai
- Address
- 311 West Superior Street, Chicago, IL, 60654, US
Technical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 6 | 2 | 14 |
| Technical Analysis | 6 | 2 | 2 |
| Moving Averages | 0 | 0 | 12 |














